Related Experiment Videos
Adrenergic mechanisms in left ventricular hypertrophy: significance and clinical implications
1University of Texas South Western Medical Center, Dallas.
Insights
Hypertension treatment aims to prevent organ damage, not just lower blood pressure. Alpha-adrenergic blockade, like with terazosin, may reverse left ventricular hypertrophy (LVH) by targeting adrenergic pathways.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension management increasingly focuses on preventing target organ damage and reversing complications.
- Left ventricular hypertrophy (LVH) is a significant cardiac consequence of hypertension, initially adaptive but potentially leading to complications.
- Reversal of LVH is a key therapeutic goal due to its association with cardiac morbidity.
Purpose of the Study:
- To explore the role of adrenergic mechanisms in the pathogenesis of LVH.
- To investigate the potential of alpha-adrenergic blockade in promoting the regression of LVH.
Main Methods:
- Review of clinical and experimental observations correlating adrenergic activity with LVH development.
- Analysis of studies demonstrating LV mass reduction with post-synaptic alpha-blockers.
- Consideration of terazosin's long duration of action in attenuating myocardial adrenergic pathways.
Main Results:
- A strong correlation exists between adrenergic activity levels and the development of LVH.
- Adrenergic blockade has been shown to induce regression of LVH.
- Post-synaptic alpha-blockers have demonstrated a reduction in left ventricular mass.
Conclusions:
- Adrenergic mechanisms play a role in the multifactorial pathogenesis of LVH.
- Alpha-adrenergic blockade represents a potential therapeutic strategy for promoting LVH regression.
- Terazosin's properties suggest its utility in managing LVH through attenuation of cardiac adrenergic pathways.
Abstract:
Emerging consensus indicates that the goal of antihypertensive therapy is not merely a reduction in the level of systemic arterial blood pressure; rather, it is prevention of target organ damage and reversal of complications. Among the clinical consequences of hypertension, left ventricular hypertrophy (LVH) is a prominent manifestation. Initially the left ventricle (LV) hypertrophies as an adaptive physiological response to an increase in afterload. However, persistence of LVH can cause a number of cardiac complications. Reversal of LVH is, therefore, likely to be of immense therapeutic benefit. A number of clinical and experimental observations have shown a close correlation between level of adrenergic activity and the development of LVH; adrenergic blockade has been shown to cause regression of LVH. Recent studies have demonstrated that post-synaptic alpha-blockers cause a reduction of LV mass. Terazosin, by virtue of its long duration of action, may attenuate the pathologic adrenergic pathways in the myocardium. These observations suggest the possible role of adrenergic mechanisms in the complex multifactorial pathogenesis of LVH and suggest the therapeutic impact of alpha-adrenergic blockade in promoting regression of LVH.